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with RLAI offers the potential for substantial cost savings in the
care of these patients.
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OBJECTIVES: To describe real life disease characteristics, clini-
cal status and socioeconomics for schizophrenia in- and outpa-
tients treated with olanzapine or haloperidol over 24 months.
METHODS: GEO is a two-year prospective naturalistic study in
Germany. Quarterly observations were made for 308 patients
under olanzapine treatment and 188 patients under haloperidol
treatment. RESULTS: Compared to haloperidol patients, more
patients included into the study under olanzapine lived at home
without care (59% vs. 39%), were employed (35% vs. 17%),
and fewer were in early retirement (30% vs. 51%). During the
observational period, olanzapine and haloperidol treatment was
stable (olanzapine: 94% retention vs. haloperidol: 92%; dosage
changes occurred in 64% vs. 47%, respectively). Concomitant
medication related to schizophrenia was prescribed less fre-
quently for olanzapine patients (52% vs. 68%). Mean disease
severity, negative and cognitive symptoms as assessed by CGI
(scales from no symptoms (one) to very severe (seven)) ranged
between three and four. Positive and depressive symptom values
were lower (mean value between two and three). During the
course of the study disease severity improved for all symptoms
with slightly more improvement in olanzapine patients (mean
change in disease severity: olanzapine 0.95; haloperidol 0.76).
Throughout the 24-month period, olanzapine patients had lower
average EPS, parkinsonism, retardation, dyskinesia and akathisia
symptom scores (none (1) to severe (6)) than haloperidol patients
(mean EPS: olanzapine 1.3; haloperidol 2.0). Weight gain,
depression and other symptoms were reported more frequently
for olanzapine (<28% vs. <11%). Nevertheless, olanzapine
patients showed a lower mean Body Mass Index (BMI) than
haloperidol patients throughout the 24-month study period.
CONCLUSIONS: Schizophrenia patients under olanzapine
treatment showed a higher degree of integration into social and
occupational environment. For olanzapine patients, all schizo-
phrenia symptoms improved over time. Throughout the study,
olanzapine patients exhibited less EPS and had a lower BMI.
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OBJECTIVE: To compare effectiveness and tolerability out-
comes of patients with schizophrenia treated with risperidone
long-acting injection and patients treated with conventional
depot antipsychotics. METHODS: Patients initiated on risperi-
done long-acting injection during a four-month index period
were compared to patients initiated on a conventional depot
antipsychotic during the same time period. Patient demograph-
ics including age, gender, diagnosis, number of previous psychi-
atric admissions and in-patient program were evaluated. The
effectiveness outcomes of antipsychotic polypharmacy, discharge
and readmission rates were compared. Neurological tolerability
was assessed as measured by the prescribing of regularly sched-
uled anticholinergic rescue medications. RESULTS: Forty
patients initiated on risperidone long-acting injection were com-
pared to 49 patients initiated on a conventional depot antipsy-
chotic. The two patient groups were demographically very
similar. The risperidone long-acting injection group was 75%
male with an average age of 41-years and 6.0 previous psychi-
atric admissions. The conventional depot group was 67% male
with an average age of 47.5 years and 5.9 previous psychiatric
admissions. Antipsychotic polypharmacy was reduced from 63%
to 31% in the risperidone long-acting injection group but
increased from 29% to 73% in the conventional depot group.
The use of anticholinergic rescue medications decreased from
47% to 12% in the risperidone long-acting injection group but
increased from 31% to 73% in the conventional depot group.
After 12-months of observation, 83% of the risperidone long-
acting injection patients had been discharged and none had been
readmitted, whereas 58% of the conventional depot group had
been discharged and, of those, 26% had already been readmit-
ted. CONCLUSION: In this difﬁcult-to-treat population of
patients, risperidone long-acting injection conferred signiﬁcant
advantages over conventional depot antipsychotics in terms of
effectiveness and tolerability. As well, the substantial differences
in discharge and readmission rates infer considerable phar-
macoeconomic advantages in favor of risperidone long-acting
injection.
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OBJECTIVES: This study estimates the annual prevalence of
schizophrenia in the U.S. based on administrative claims data
analyses and a comprehensive literature review. METHODS:
The 2002 annual prevalence rate of schizophrenia in the U.S.
was estimated separately for privately insured, government
insured (Medicare, Medicaid), and uninsured populations. The
2002 annual prevalence for privately insured individuals was cal-
culated based on a de-identiﬁed administrative claims database
of approximately 3.0 million privately insured beneﬁciaries cov-
ering the period from 1999 to 2003. The 2002 prevalence of
Medicaid enrollees was calculated from Medi-Cal claims cover-
ing the period from 2000–2002. The 2002 schizophrenia preva-
lence in Medicare population was calculated as a weighted
average of the prevalence rates of Medicaid/Medicare dual eligi-
bles and private insurance program enrollees over 65. Published
statistics were used to estimate the prevalence of schizophrenia
in the uninsured population and to weight prevalence rates in
different populations to estimate the 2002 annual schizophrenia
prevalence in the general U.S. population. RESULTS: The annual
prevalence rate of schizophrenia in the U.S. in 2002 was esti-
mated at 0.5%. The Medicaid population was identiﬁed as
having the highest schizophrenia prevalence rate in the U.S.
(1.7% for non Medicare dual eligible enrollees), whereas annual
schizophrenia prevalence rates in Medicare and privately insured
population were 0.7% and 0.1%, respectively. The disease was
also more prevalent in the uninsured population (1.1%). Preva-
lence rates for women were highest in an older age group (56–65
years), whereas men’s prevalence rates peaked somewhat earlier
(46–55 years). CONCLUSIONS: The results suggest that schiz-
ophrenia may be more prevalent in the U.S. general population
than previously estimated in some epidemiology survey studies,
especially given the fact that claims database analyses usually
